Context Therapeutics (CNTX) Short term Debt (2020)
Context Therapeutics' (CNTX) quarterly Short term Debt came in at $5.8 million in Q4 2020.
Context Therapeutics (CNTX) Short term Debt (2020) Analysis & Trends
Context Therapeutics has disclosed Short term Debt across 1 years of filings, most recently posting $5.8 million for Q4 2020.
- Short term Debt for Q4 2020 came in at $5.8 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was $5.8 million (changed N/A YoY), and the FY2020 annual result was $5.8 million, changed N/A from the prior year.
- Short term Debt came in at $5.8 million for Q4 2020 at Context Therapeutics.
- In the past five years, Short term Debt ranged from a high of $5.8 million in Q4 2020 to a low of $5.8 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | Context Therapeutics | 166.57 Mn | 166.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 5.83 Mn |